The global central nervous system lymphoma treatment market is slated to reach a valuation of USD 123.2 billion in 2023. According to Future Market Insights, the market is expected to grow at a 5.2% CAGR until 2033, valued at USD 205.3 billion.
The central nervous system lymphoma market report provides current treatment practices, emerging drugs, Central Nervous System Lymphoma market share of the individual therapies, and current and forecasted Central Nervous System Lymphoma Market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Central Nervous System Lymphoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
New research activities conducted in the sphere of mental health and psychiatric disorders have increased the demand for treatment and therapeutic opportunities available in the central nervous system lymphoma market.
Lymphoma of the central nervous system, both primary and secondary, represents a rare subset of non-Hodgkin lymphoma. Primary central nervous system lymphoma refers to those cases confined to the central nervous system parenchyma, dura, leptomeninges, cranial nerves, and spinal cord or the intraocular compartment in immunocompetent patients. On the other hand, secondary CNS lymphoma refers to systemic non-Hodgkin's lymphoma that has disseminated to the CNS. Historically, the prognosis of primary central nervous system lymphoma has been very dismal, with overall survival of 1.5 months when untreated, and a 5-year survival rate of 30%. This activity describes the pathophysiology of CNS lymphoma and highlights the role of the interprofessional team in its management.
The Central Nervous System Lymphoma market report gives a thorough understanding of central nervous system lymphoma by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. This segment of the report covers the detailed diagnostic methods or tests for Central Nervous System Lymphoma.
| Attributes | Details |
|---|---|
| Expected Market Value (2023) | USD 123.2 billion |
| Projected Forecast Value (2033) | USD 205.3 billion |
| Global Growth Rate (2023 to 2033) | 5.2% |
| Base Year value (2022) | USD 117.6 billion |
| Forecast period | 2023 to 2033 |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global central nervous system (CNS) lymphoma treatment market is expected to surge at a CAGR of 5.2% for the forecast period compared to the historic CAGR from 2018 to 2022 of 4.66%, as per Future Market Insights, a provider of market research and compared to the competitive intelligence.
Central Nervous System (CNS) Lymphoma or microglioma is a disease in which cancer cells are formed in the lymph tissue of the brain or spinal cord. This is observed primarily in patients with very weak immune systems, patients suffering from immunosuppression, and AIDS patients. Patients who have undergone recent kidney or other organ transplants are also at a high risk of having CNS lymphoma due to their low count of T-Cells or low level of immunity.
The major symptoms of this disease include headaches, memory problems, drowsiness, seizures, nausea, vomiting, personality changes, throat infection, body weakness, and sometimes, even hearing loss and double vision. This disease may occur in all age groups; however, it is mostly noticed in people in the 50+ age group.
The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. It also provides information on unit shipments. These provide the key market participants with the necessary business intelligence and help them understand the future of the CNS lymphoma market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis.
The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats. The key areas of focus include the types of prognosis and diagnosis in the CNS Lymphoma market and their treatment methods.
Several mutations in tumor suppressor and proto-oncogenes involved in B cell activation, differentiation, and apoptosis are believed to contribute to the development of CNS lymphoma. Somatic hypermutations in proto-oncogenes such as MYC, PAX5, Rho/TTF, and PIM1 as well as the tumor suppressor genes such as PRDM1 have been demonstrated in CNS lymphoma cases. NF-KB signaling is believed to play a role in disease pathogenesis.
The up-regulation of activators within the NF-KB pathway such as MYD88, CADR11, and CD79 as well as suppression of NF-KB inhibitors such as TNFAIP3 have presented in individuals with CNS lymphoma. Expression of MYD88 and CD79B mutations in secondary CNS lymphoma is considerably lower than in primary CNS lymphoma, which suggests different pathogenesis. Aberrant regulation of the JAK/STAT pathway is also implicated. Increased levels of IL-10, A JAK/STAT mediator are seen in CSF analysis of primary CNS lymphoma patients and are often associated with a worse prognosis.
It is still unclear whether cells of primary CNS lymphoma first arise from within the CNS itself, or rather systemically then travel to the CNS via peripheral blood and further accumulate other mutations.
But nowadays, the efficacy of MTX has meant that the investigation of most of these novel treatment strategies has been in the relapsed/refractory setting. Only recently are studies starting to incorporate the use of some of these newer agents into upfront treatment, largely in combination with MTX. It remains to be seen whether any of these agents will obviate the need for MTX and the most part, this is not being studied except in patients who are considered ineligible for MTX-based therapy.
While MTX is effective, it necessitates frequent hospitalizations, leading to time away from work and family. Additionally, it confers a risk of MTX-related toxicity, as well as complications associated with inpatient admissions such as delirium, urinary tract infections, and thromboembolic events. Many of the novel therapies are oral and most can be administered in the outpatient setting. If they prove to be as effective as MTX, this may lead to a new treatment paradigm for PCNSL.
As we continue to develop novel strategies for this disease, it will become increasingly important to develop minimally invasive biomarkers. Traditionally, patients are monitored for recurrence with routine MRIs and possibly CSF sampling and ocular exams, depending on their presentation. Monitoring of biomarkers such as interleukin-10 (IL-10) may help monitor treatment response and allow for early detection of relapse [56,87]. Detection of circulating tumor DNA (ctDNA) may serve a similar role while allowing for the detection and confirmation of genetic arrangements.
While this technology has been unsuccessful in the serum of patients with PCNSL [88] in CSF, ctDNA has been used to detect molecular alterations [59,89]. Studies are ongoing to determine whether the detection of ctDNA in the CSF is of prognostic import and can be used to monitor treatment response (NCT04401774). Monitoring of ctDNA in the CSF may also allow for monitoring of the presence of targetable mutations.
Technological progress made in the healthcare sector to foster growth in the market
There has been an augmented prevalence of the illness that is likely to influence the growth of global CNS lymphoma treatment in the years to come. Such growth in the market is ascribed to increased awareness regarding the disease. In addition, technological progress made in the healthcare sector together with increased government spending is likely to drive the growth of the market in the future.
Enhanced biomarkers are triggering the market expansion
Intriguing opportunities are created so that the companies present worldwide for CNS lymphoma treatment for the usage of distinctive and technologically advanced biomarkers in diagnosis and management purposes. These biomarkers assist medical practitioners in identifying the symptoms more quickly than the traditional ones.
The genetic, and radiographic biomarkers are among the few of the newly improved biomarkers that are progressively being employed for diagnosis and treatment reasons worldwide. The market for CNS lymphoma treatment is anticipated to rise over the next few years as a result of the development efforts for creating novel, technologically enhanced detection technologies for effective biomarkers.
Principal Consultant
Time-consuming approval process
The process of approval of central nervous system therapeutic and the drugs used to treat central nervous system diseases is very time-consuming. This factor restricts the market growth. Furthermore, research and development require a higher amount of investment which hampers market growth. It is a longer developmental and approval process. The higher cost per approval impedes the central nervous system therapeutic market growth.
Stringent regulatory framework
The stringent regulations of the governments challenge the central nervous system therapeutic market growth. The therapeutic drugs used to treat the central nervous system must go through an approval process. This process is very strict, and various stringent regulations are imposed by the government, which further challenges market growth.
A rise in eye cancer cases along the lymphoma will boost the growth
During the forecast period, the North American market is assumed to be the most volatile one, where according to the American Cancer Society’s projections are estimated:
Primary intraocular lymphoma can strike at any age and mostly rises with age. It is less prevalent than secondary eye malignancies, the lymphomas that have progressed from any other area of the body part to the eye. Also, adult melanomas are often found to affect the eye and orbit, mostly developing in other parts of the body, where more than 90% of melanomas have cutaneous regions.
Increasing healthcare developments
The market in this area is anticipated to be driven by the rise in healthcare spending, the pharmaceutical industry’s rapid growth, and significant unmet demands. The Asia-Pacific central nervous system (CNS) lymphoma treatment market treatment is expected to grow during the projected period as a result of technological developments in the market and also due to the rise in disposable income.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Radiotherapy will gain the dominant market share
Due to its high sensitivity to radiation, patients with newly diagnosed central nervous system lymphomas have traditionally received treatment with whole-brain radiotherapy (WBRT). While the initial responses were high, early relapse, as well as radiation-associated neurotoxicity, was common among survivors. Moreover, the median overall survival was 12 to 18 months when WBRT was the sole treatment. With the introduction of high-dose methotrexate (HD-MTX) chemotherapy regimens in the 1970s, improved survival occurred among individuals with CNS lymphoma. When used as a sole treatment, the median overall survival with high-dose methotrexate was 25 to 55 months.
The demand for hospital/clinical laboratories will be more during the forecast period.
According to a report by Future Market Insights, the hospital/clinical laboratories would grow within the anticipated time frame. This market sector is expected to hold a greater share of the worldwide market from 2023 to 2033.
Due to the rise in population and advancement in technologies, a growing number of people are more prone to visiting hospitals for advice on treatment related to CNS lymphoma treatment, where they will be provided with proper care at each interval of time. As a result, individuals more pertain towards their health and well-being. Thus, the majority of consumers are expected to only buy medications from hospital pharmacies.
The publisher performs Competitive and Market Intelligence analysis of the Central Nervous System Lymphoma Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Some of the important developments of the key players in the market are
| Report Attribute | Details |
|---|---|
| Growth Rate | 5.2% CAGR |
| Base Year Estimation | 2022 |
| Market Value in 2023 | USD 123.2 billion |
| Market Value in 2033 | USD 205.3 billion |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | USD billion for Value and CAGR from 2023 to 2033 |
| Reports Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Treatment, End User, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | United States, Canada, Brazil, Mexico, Rest of Latin America, Germany, United Kingdom, France, Spain, Italy, Rest of Europe, India, Malaysia, Singapore, Thailand, Rest of South Asia, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel, Rest of MEA |
| Key Companies Profiled | Amgen; Dr. Reddy’s laboratories; Roche; Bristol-Myers Squibb; Cipla; Merck; Novartis; AbbVie; Fresenius SE & Co. KGaA; Sanofi S.A |
| Customization Scope | Available on Request |
Technological progress in the healthcare sector fuels market growth.
Cipla, Merck, and Novartis are the key market players.
Radiotherapy is estimated to gain the dominant market.
This market is valued at USD 123.2 billion in 2023.
The market was valued at USD 117.6 billion in 2022.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 5.1. Chemotherapy 5.2. Radiation Therapy 5.3. Steroid Therapy 5.4. Targeted Therapy 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 6.1. Hospitals 6.2. Clinics 6.3. Ambulatory Surgical Centres 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Europe 7.4. South Asia 7.5. East Asia 7.6. Oceania 7.7. MEA 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Key Countries Market Analysis 16. Market Structure Analysis 17. Competition Analysis 17.1. Amgen 17.2. Dr. Reddy Laboratories 17.3. Roche 17.4. Bristol-Myers Squibb 17.5. Cipla 17.6. Merck 17.7. Novartis 17.8. AbbVie 17.9. Fresenius SE & Co. KGaA 17.10. Sanofi S.A 18. Assumptions & Acronyms Used 19. Research Methodology
Healthcare
December 2022
REP-GB-1655
250 pages
Explore Healthcare Insights
View Reports
Central Nervous System Lymphoma Treatment Market
